Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Prime Medicine, Inc. Common Stock

PRME

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Last trade $3.90
Day change -$0.29 (-6.92%)
Day range $3.87 – $4.40
Volume 3,152,989
Market cap $934M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$934.34M
Price / earnings
—
Price / book
110.74×
Price / sales
132.32×
EV / sales
124.55×
EV / EBITDA
-5.02×

Profitability

Earnings per share
-$0.79
Return on assets
-82.46%
Return on equity
-2,090.23%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.19×
Quick ratio
1.19×
Cash ratio
1.02×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$158.54M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PRME, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$4.21M$1.15M$856K$838K$1.23M$1.12M$1.45M$2.18M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$4.21M$1.15M$856K$838K$1.23M$1.12M$1.45M$2.18M
Selling, general and administrative$10.02M$11.04M$17.41M$14.74M$11.21M$13.12M$13.28M$12.3M
Research and development$34.12M$33.4M$34.11M$34.71M$43.99M$41.38M$40.56M$34.1M
Total operating expenses$44.14M$44.44M$51.51M$49.45M$55.2M$54.49M$53.85M$46.41M
Operating income-$39.93M-$43.29M-$50.65M-$48.61M-$53.97M-$53.38M-$52.39M-$44.22M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$39.04M-$42.11M-$49.12M-$46.08M-$50.58M-$52.59M-$51.89M-$42.28M
Income taxes$0$0$0$0$0$0$0$0
Net income-$39.04M-$42.11M-$49.12M-$46.08M-$50.58M-$52.59M-$51.89M-$42.28M
Net income attributable to common shareholders-$39.04M-$42.11M-$49.12M-$46.08M-$50.58M-$52.59M-$51.89M-$42.28M
EBITDA-$38.17M-$41.5M-$48.8M-$46.73M-$52.09M-$51.51M-$50.69M-$42.51M
Basic earnings per share-$0.22-$0.24-$0.28-$0.26-$0.32-$0.41-$0.40-$0.32
Diluted earnings per share-$0.22-$0.24-$0.28-$0.26-$0.32-$0.41-$0.40-$0.32

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates

Prime Medicine (PRME) reported a quarterly loss of $0.22 per share, beating consensus estimates of $0.23 loss by 4.35%, but missed revenue expectations with $4.21 million versus the consensus estimate, down 25.8%. The stock has outperformed the S&P 500 by 12.6% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) reported a quarterly loss of $0.17 per share, missing the consensus estimate of $0.15 loss by 13.33%. Revenue came in at $0.3 million, significantly missing estimates by 88.43%. The company has failed to beat consensus estimates for four consecutive quarters. Despite a 190% year-to-date gain, ABSI received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Prime Medicine Announces Pricing of Public Offering of Common Stock

Prime Medicine (Nasdaq: PRME), a biotechnology company focused on gene editing therapies, announced a public offering of 35.7 million shares at $3.50 per share, expected to raise approximately $125 million. The offering is expected to close on November 12, 2026, with Jefferies, TD Cowen, and Goldman Sachs serving as joint book-running managers.

Zacks Investment Research

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?

Prime Medicine (PRME) shares jumped 23.2% to $5.36 following FDA clearance for its investigational therapy PM647 for alpha-1 antitrypsin deficiency and progress in its gene-editing pipeline. The company is expected to report a quarterly loss of $0.23 per share with revenues up 361.6% year-over-year. However, with unchanged earnings estimate revisions over the past 30 days, the stock carries a Zacks Rank #3 (Hold) rating, suggesting caution about sustained momentum.

Zacks Investment Research

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 10, 2019$0.80Sep 12, 2019recurring
Jun 14, 2019$0.20Jun 28, 2019recurring
Dec 18, 2018$0.2133Dec 31, 2018recurring
Sep 14, 2018$0.2327Sep 28, 2018recurring
Jun 21, 2018$0.1457Jun 29, 2018recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.